1.	Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Phase: Phase III Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Active Age: not specified Sponsor: NCI, Other Protocol IDs: 2448.00, NCI-2010-02035, P01CA018029, NCT01231412
2.	Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant Phase: Phase II, Phase I Type: Treatment Status: Active Age: Under 75 Sponsor: NCI, Other Protocol IDs: 1825.00, NCI-2010-00230, P01CA078902, FHCRC-1825.00, 5605, SUPERGEN-FHCRC-1825.00, NCT00096161
3.	Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 75 Sponsor: NCI, Other Protocol IDs: CDR0000447204, P30CA016058, OHSU-HEM-05011-L, OHSU-210, NCT00245037
4.	Fludarabine, Busulfan, and Alemtuzumab Followed By Donor Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disease Phase: Phase II, Phase I Type: Treatment Status: Active Age: 70 and under Sponsor: Other Protocol IDs: BCM-H-19386, BCM-FAB, H 19386, NCT00625144
5.	Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 12-0132, NCT00943319
6.	To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 2 to 20 Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: 100220, IND 59,056, NCT01222780
7.	Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT) Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: RGI-2001-02, NCT01379209
8.	Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 2011-001, NCT01416428
9.	Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 65 Sponsor: Other Protocol IDs: 201303012, NCT01747499
10.	Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow Phase: Phase II Type: Treatment Status: Active Age: 8 to 80 Sponsor: NHLBI Protocol IDs: 990050, 99-H-0050, NHLBI-99-H-0050, NCT00003838
11.	Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant For Hematologic Cancer Phase: Phase II Type: Supportive care, Treatment Status: Active Age: Under 75 Sponsor: NCI, Other Protocol IDs: 1898.00, NCI-2010-00267, P01HL036444, P01CA078902, FHCRC-1898.00, 5788, NCT00089011
12.	Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease Phase: Phase II Type: Treatment Status: Active Age: 10 to 75 Sponsor: NHLBI Protocol IDs: NHLBI-06-H-0248, NHLBI-IDE-13058, NCT00398346
13.	Allogeneic Transplantation Using TL1 & ATG for Older Patients With Hematologic Malignancies Phase: Phase II Type: Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: BMT153, 78998, 11960, NCT00185640
14.	Laboratory-Treated T Lymphocytes in Preventing Graft-Versus-Host Disease in Patients Undergoing Donor Peripheral Stem Cell Transplant for Hematologic Cancer or Other Disease Phase: Phase II Type: Treatment Status: Active Age: 18 to 75 Sponsor: NHLBI Protocol IDs: NHLBI-07-H-0136, 07-H-0136
15.	Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies Phase: Phase II Type: Treatment Status: Active Age: 2 to 21 Sponsor: Other Protocol IDs: HIFLEX, NCT00566696
16.	Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies Phase: Phase II Type: Treatment Status: Active Age: 18 to 65 Sponsor: Other Protocol IDs: 0704-19 IUCRO-0184, NCT00593554
17.	Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: Pro00003567, NCT00597714
18.	Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant Phase: Phase II Type: Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: 2007LS072, UMN-MT2007-07, 0707M11845, UMN-2007LS072, NCT00617929
19.	Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell Transplant Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: umcc 2008.095, NCT00810602
20.	Immune Response After Stem Cell Transplant in HIV-Positive Patients With Hematologic Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 75 and under Sponsor: NCI, Other Protocol IDs: 2212.00, NCI-2009-01244, P01CA018029, U19AI096111, NCT00968630
21.	T-cell Depleted Alternative Donor Transplantation Phase: Phase II Type: Supportive care, Treatment Status: Active Age: 30 and under Sponsor: Other Protocol IDs: LCH BMT 09-01, NCT00968864
22.	Study of Reduced Intensity Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT) to Treat Hematologic Malignancies and Hematopoietic Failure States Phase: Phase II Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: 09-0679-04, NCT00997386
23.	Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 0 to 75 Sponsor: NCI, Other Protocol IDs: 2241.00, NCI-2009-01334, P01CA078902, NCT01008462
24.	CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant Phase: Phase II Type: Treatment Status: Active Age: 0 to 26 Sponsor: Other Protocol IDs: L 10,321, NYMC 525, NCT01049854
25.	Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2 Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: 2010-0284, NCT01200485